A股異動 | 邁克生物(300463.SZ)午後拉昇漲超8% 新冠抗原自測產品取得國內註冊證書
格隆匯12月23日丨邁克生物(300463.SZ)午後直線拉昇,現漲8.22%報19.09元,暫成交1.7億元,最新市值117億元。邁克生物今日午間公佈,公司於近日收到國家藥品監督管理局頒發的關於新型冠狀病毒(2019-nCoV)抗原檢測試劑盒(膠體金法)的《醫療器械註冊證》。此次公司新型冠狀病毒(2019-nCoV)抗原檢測試劑盒(膠體金法)在國內取得醫療器械註冊證書,標誌着公司可為國內市場提供適應全場景的新冠病毒檢測整體解決方案,有利於進一步提升公司新冠檢測產品競爭力,為疫情防護提供更多助力。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.